Business
Piramal Pharma Solutions Announces Partnership with Botanix to Support Drug Substance Development
Piramal Pharma Solutions (PPS), a leading global Contract Development and Manufacturing Organization (CDMO) and part of Piramal Pharma Ltd. (NSE: PPLPHARMA) (BSE: 543635), has entered a manufacturing and supply arrangement with Botanix SB Inc., a subsidiary of Botanix Pharmaceuticals Limited (ABN 70 009 109 755) (ASX:BOT) ("Botanix"), a commercial dermatology company.
About this update from Piramal Pharma Limited
[{"type":"list","items":[{"val":[{"type":"text","content":"Piramal Pharma Solutions has entered into an agreement with Botanix SB Inc., a subsidiary of Botanix Pharmaceuticals Limited, to support the development and commercial supply of Sofdra®.","length":186,"tagName":"p"}]},{"val":[{"type":"text","content":"Sofdra is the first and only FDA-approved new chemical entity (NCE) for the treatment of primary axillary hyperhidrosis.","length":120,"tagName":"p"}]},{"val":[{"type":"text","content":"Through this partnership, Piramal Pharma Solutions will leverage the strength of its North American drug substance facilities to support robust, consistent patient access to Sofdra.","length":181,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":487,"olType":false},{"type":"text","content":"MUMBAI, India, May 18, 2026 /PRNewswire/ -- Piramal Pharma Solutions (PPS), a leading global Contract Development and Manufacturing Organization (CDMO) and part of Piramal Pharma Ltd. (NSE: PPLPHARMA) (BSE: 543635), has entered a manufacturing and supply arrangement with Botanix SB Inc., a subsidiary of Botanix Pharmaceuticals Limited (ABN 70 009 109 755) (ASX:BOT) ("Botanix"), a commercial dermatology company.","length":429,"tagName":"p"},{"type":"image","alt":"Peter DeYoung, CEO, Piramal Global Pharma","displaySize":"","headline":null,"caption":"Peter DeYoung, CEO, Piramal Global Pharma","className":"","disableSlideshowImg":false,"size":{"original":{"width":320,"height":400,"url":"https://media.zenfs.com/en/prnewswire.com/18593ac516288da7d1a1253c2eb2bc20"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/NY6yJwaUM5TMasnwQkL.dQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTY0MDtoPTgwMA--/https://media.zenfs.com/en/prnewswire.com/18593ac516288da7d1a1253c2eb2bc20","width":320,"height":400},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/NY6yJwaUM5TMasnwQkL.dQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTY0MDtoPTgwMA--/https://media.zenfs.com/en/prnewswire.com/18593ac516288da7d1a1253c2eb2bc20","width":320,"height":400}}},{"type":"text","content":"Under this arrangement, PPS will initiate development and validation services for Sofpironium Bromide, the active pharmaceutical ingredient (API) in Sofdra®, at its Riverview, Michigan facility. Following successful regulatory approval at Riverview, PPS and Botanix will consider validating the process at PPS's Aurora, Canada facili...